OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
EMA Recommends Approval of 10 Drugs
The agency recommended approval of 11 drugs, including three cancer drugs, in September.
Updated 9/21/16
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of 10 drugs during their Sept. 12–15, 2016 meeting. The approved drugs treat a range of conditions including different forms of cancer, type 2 diabetes, secondary hyperparathyroidism, heart failure, and HIV.
CHMP recommended the following:
- Conditional marketing authorization was given to Lartruvo, for the treatment of adults with advanced soft tissue sarcoma.
- Marketing authorization for Ibrance, for the treatment of locally advanced or metastatic breast cancer.
- Conditional marketing authorization for Ninlaro (ixazomib) for the treatment of multiple myeloma.
- Approval of Glyxambi (empagliflozin/linagliptin) for the treatment of type 2 diabetes.
- Approval of Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism.
- Positive opinion for Chenodeoxycholic acid sigma-tau (chenodeoxycholic acid) for the treatment of cerebrotendinous xanthomatosis.
CHMP also recommended the approval of four generic drugs: Ivabradine JensenR (ivabradine) and Ivabradine Zentiva (ivabradine) to treat angina pectoris and heart failure, Emtricitabine/ Tenofovir disoproxil Zentiva (emtricitabine/tenofovir disoproxil) to treat HIV infection, and Granpidam (sildenafil) for the treatment of patients with pulmonary arterial hypertension.
Source: EMA
